Featured Research

from universities, journals, and other organizations

Structure Of Protein That Helps Feed Cancerous Tumors Is Deciphered At Cornell University, Possibly Leading To More Effective Drugs

Date:
November 13, 1998
Source:
Cornell University
Summary:
For some years now, cancer researchers have known that cancerous tumors are fed by nutrients and oxygen through blood vessels generated by endothelial cells. Now the hope is to develop drugs to prevent the cells from forming the blood vessels, thus starving the tumors.

ITHACA, N.Y. -- For some years now, cancer researchers have known that cancerous tumors are fed by nutrients and oxygen through blood vessels generated by endothelial cells. Now the hope is to develop drugs to prevent the cells from forming the blood vessels, thus starving the tumors.

Researchers working at Cornell University have brought this goal closer by deciphering the three-dimensional structure of a protein that helps cells build new blood vessels. The researchers also have discovered how a drug now in clinical trials binds to the protein methionine aminopetidase-2, or MetAP-2, for short.

Writing today (Nov. 13, 1998) in the journal Science, a research team led by Jon Clardy, Cornell's Horace White Professor of Chemistry and Chemical Biology, and Shenping Liu, Cornell visiting scientist, note that this new understanding of MetAP-2 might help chemists design more effective drugs.

"Our structure provides a better basis for designing drugs against cancer," says Liu. Because the protein, MetAP-2, was specifically shown to bind to the drug, he says, the research could pave the way for anti-cancer drugs with fewer side effects. The more specific the drug, the fewer the side effects, he says.

The researchers focused on the effects of fumagillin (pronounced foo-MAA-jill-in), a small organic molecule discovered from the fungus Aspergillus fumigatus. Earlier research had first discovered that fumagillin inhibits the formation of new blood vessels, a process called angiogenesis, and that it inhibits MetAP-2.

A semi-synthetic drug, TNP-470, a fumagillin derivative, currently is undergoing human clinical testing as an anti-cancer agent. By uncovering the three-dimensional structure of the targeted protein, MetAP-2, the new results indicate precisely how the drug binds to the protein.

Because TNP-470 is broken down quickly in the body, researchers are trying to develop improved versions. The Cornell research, by showing precisely how the drug fits into the protein, is an important step for pharmaceutical designers to synthesize better drugs, Clardy says.

Interfering with the blood flow into the tumor prevents growth. However, Clardy warns, "We need to be cautious and not get our hopes too high." Several research groups are trying to figure out how MetAP-2 inhibits the formation of new blood vessels, he says, and the new drugs will take years of development and testing.

Clardy and his colleagues determined the three-dimensional structure of human MetAP-2 using X-ray crystallography at MacCHESS, the world-renowned Macromolecular Diffraction Facility at Cornell High Energy Synchrotron Source (CHESS). The synchrotron produces high-intensity, high-energy X-ray beams for scientific research.

MacCHESS is supported by the National Institutes of Health for research in drug design, protein and virus crystallography and data collection from synchrotron sources. CHESS is supported by the National Science Foundation.

The research, "Structure of Human Methionine Aminopeptidase-2 Complexed with Fumagillin," appears in the Nov. 13 journal Science. It was authored by Clardy; Liu; Joanne Widom, Cornell chemistry researcher; Craig Crews, Yale University professor; and C.W. Kemp of Kemp Biotechnologies, Frederick, Md. Funding for the research was provided by U.S. Public Health Service grants.

-30-

EDITORS: A similar paper is being released today by the Proceedings of the National Academy of Sciences, "Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2," by J. O. Liu, Massachusetts Institute of Technology, et al. It is available at http://www.nas.edu/includes/liu.htm.


Story Source:

The above story is based on materials provided by Cornell University. Note: Materials may be edited for content and length.


Cite This Page:

Cornell University. "Structure Of Protein That Helps Feed Cancerous Tumors Is Deciphered At Cornell University, Possibly Leading To More Effective Drugs." ScienceDaily. ScienceDaily, 13 November 1998. <www.sciencedaily.com/releases/1998/11/981113081859.htm>.
Cornell University. (1998, November 13). Structure Of Protein That Helps Feed Cancerous Tumors Is Deciphered At Cornell University, Possibly Leading To More Effective Drugs. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1998/11/981113081859.htm
Cornell University. "Structure Of Protein That Helps Feed Cancerous Tumors Is Deciphered At Cornell University, Possibly Leading To More Effective Drugs." ScienceDaily. www.sciencedaily.com/releases/1998/11/981113081859.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins